临床误诊误治

参考文献

[1] KIM B E,NEVITT T,THIELE D J.Mechanisms for copper acquisition,distribution and regulation[J].Nat Chem Biol,2008,4(3):176-185.

[2] LUTSENKO S.Human copper homeostasis:a network of interconnected pathways[J].Curr Opin Chem Biol,2010,14(2):211-217.

[3] TSVETKOV P,COY S,PETROVA B,et al.Copper induces cell death by targeting lipoylated TCA cycle proteins[J].Science,2022,375(6586):1254-1261.

[4] GE E J,BUSH A I,CASINI A,et al.Connecting copper and cancer:from transition metal signalling to metalloplasia[J].Nat Rev Cancer,2022,22(2):102-113.

[5] DIXON S J,LEMBERG K M,LAMPRECHT M R,et al.Ferroptosis:an iron-dependent form of nonapoptotic cell death[J].Cell,2012,149(5):1060-1072.

[6] ACKERMAN C M,LEE S,CHANG C J.Analytical methods for lmaging metals in biology:from transition metal metabolism to transition metal signaling[J].Anal Chem,2017,89(1):22-41.

[7] HARE D J,NEW E J,DE JONGE M D,et al.Imaging metals in biology:balancing sensitivity,selectivity and spatial resolution[J].Chem Soc Rev,2015,44(17):5941-5958.

[8] COBINE P A,MOORE S A,LEARY S C.Getting out what you put in:copper in mitochondria and its impacts on human disease[J].Biochim Biophys Acta Mol Cell Res,2021,1868(1):118867.

[9] SHANBHAG V,JASMER-MCDONALD K,ZHU S,et al.ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis[J].Proc Natl Acad Sci U S A,2019,116(14):6836-6841.

[10] GUNJAN D,SHALIMAR,NADDA N,et al.Hepatocellular carcinoma:an unusual complication of longstanding wilson disease[J].J Clin Exp Hepatol,2017,7(2):152-154.

[11] BLOCKHUYS S,CELAURO E,HILDESJ? C,et al.Defining the human copper proteome and analysis of its expression variation in cancers[J].Metallomics,2017,9(2):112-123.

[12] LOPEZ J,RAMCHANDANI D,VAHDAT L.Copper depletion as a therapeutic strategy in cancer[J].Met Ions Life Sci,2019,19.

[13] ISHIDA S,ANDREUX P,POITRY-YAMATE C,et al.Bioavailable copper modulates oxidative phosphorylation and growth of tumors[J].Proc Natl Acad Sci U S A,2013,110(48):19507-19512.

[14] WOOTON-KEE C R,ROBERTSON M,ZHOU Y,et al.Metabolic dysregulation in the Atp7b-/-Wilson's disease mouse model[J].Proc Natl Acad Sci U S A,2020,117(4):2076-2083.

[15] YANG H,RALLE M,WOLFGANG M J,et al.Copper-dependent amino oxidase 3 governs selection of metabolic fuels in adipocytes[J].PLoS Biol,2018,16(9):e2006519.

[16] TSANG T,POSIMO J M,GUDIEL A A,et al.Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma[J].Nat Cell Biol,2020,22(4):412-424.

[17] GAGGELLI E,KOZLOWSKI H,VALENSIN D,et al.Copper homeostasis and neurodegenerative disorders (Alzheimer's,prion,and Parkinson's diseases and amyotrophic lateral sclerosis)[J].Chem Rev,2006,106(6):1995-2044.

[18] O'DAY S,GONZALEZ R,LAWSON D,et al.Phase Ⅱ,randomized,controlled,double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage Ⅳ metastatic melanoma[J].J Clin Oncol,2009,27(32):5452-5458.

[19] BANDMANN O,WEISS K H,KALER S G.Wilson's disease and other neurological copper disorders[J].Lancet Neurol,2015,14(1):103-113.

[20] CUI L,GOUW A M,LAGORY E L,et al.Mitochondrial copper depletion suppresses triple-negative breast cancer in mice[J].Nat Biotechnol,2021,39(3):357-367.

[21] AGGARWAL A,BHATT M.Advances in treatment of wilson disease[J].Tremor Other Hyperkinet Mov (N Y),2018,8:525.

[22] O'DAY S J,EGGERMONT A M,CHIARION-SILENI V,et al.Final results of phase Ⅲ SYMMETRY study:randomized,double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma[J].J Clin Oncol,2013,31(9):1211-1218.

[23] LI S R,BU L L,CAI L.Cuproptosis:lipoylated TCA cycle proteins-mediated novel cell death pathway[J].Signal Transduct Target Ther,2022,7(1):158.

[24] TSVETKOV P,DETAPPE A,CAI K,et al.Mitochondrial metabolism promotes adaptation to proteotoxic stress[J].Nat Chem Biol,2019,15(7):681-689.

[25] BIAN Z,FAN R,XIE L.A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma[J].Genes (Basel),2022,13(5):851.

[26] D?RSAM B,FAHRER J.The disulfide compound α-lipoic acid and its derivatives:a novel class of anticancer agents targeting mitochondria[J].Cancer Lett,2016,371(1):12-19.

[27] RAYESS H,WANG M B,SRIVATSAN E S.Cellular senescence and tumor suppressor gene p16[J].Int J Cancer,2012,130(8):1715-1725.

[28] BUI T O,DAO V T,NGUYEN V T,et al.Genomics of clear-cell renal cell carcinoma:a systematic review and meta-analysis[J].Eur Urol,2022,81(4):349-361.

[29] ZHANG G,SUN J,ZHANG X.A novel cuproptosis-related lncRNA signature to predict prognosis in hepatocellular carcinoma[J].Sci Rep,2022,12(1):11325.

[30] XU Z,JIANG S,MA J,et al.Comprehensive analysis of ferroptosis-related lncrnas in breast cancer patients reveals prognostic value and relationship with tumor immune microenvironment[J].Front Surg,2021,8:742360.

[31] YANG L,WU Y,XU H.Identification and validation of a novel six-lncRNA-based prognostic model for lung adenocarcinoma[J].Front Oncol,2022,11:775583.

[32] HUANG D P,LIAO M M,TONG J J,et al.Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma[J].Aging (Albany NY),2021,13(22):24621-24639.

[33] HUANG A C,ZAPPASODI R.A decade of checkpoint blockade immunotherapy in melanoma:understanding the molecular basis for immune sensitivity and resistance[J].Nat Immunol,2022,23(5):660-670.

[34] LV H,LIU X,ZENG X,et al.Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma[J].Front Pharmacol,2022,13:930041.

[35] CHEN B,ZHOU X,YANG L,et al.A cuproptosis activation scoring model predicts neoplasm-immunity interactions and personalized treatments in glioma[J].Comput Biol Med,2022,148:105924.

[36] KUMAR P,AGGARWAL R.An overview of triple-negative breast cancer[J].Arch Gynecol Obstet,2016,293(2):247-269.

[37] SHA S,SI L,WU X,et al.Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer[J].Front Immunol,2022,13:922780.

[38] YANG L,YU J,TAO L,et al.Cuproptosis-related lncrnas are biomarkers of prognosis and immune microenvironment in head and neck squamous cell carcinoma[J].Front Genet,2022,13:947551.

[39] HAN J,HU Y,LIU S,et al.A newly established cuproptosis:associated long non-coding rna signature for predicting prognosis and indicating immune microenvironment features in soft tissue sarcoma[J].J Oncol,2022,2022:8489387.

[40] XU M,MU J,WANG J,et al.Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma[J].Front Oncol,2022,12:961213.